S&P 500
(0.37%) 5 118.81 points
Dow Jones
(0.28%) 38 345 points
Nasdaq
(0.38%) 15 989 points
Oil
(-0.51%) $83.42
Gas
(2.81%) $1.977
Gold
(0.05%) $2 348.30
Silver
(-0.02%) $27.53
Platinum
(3.13%) $950.95
USD/EUR
(-0.07%) $0.934
USD/NOK
(-0.10%) $11.01
USD/GBP
(-0.34%) $0.798
USD/RUB
(1.32%) $93.08

Aktualne aktualizacje dla Prescient Therapeutics [PTX.AX]

Giełda: ASX Branża: Pharmaceuticals, Biotechnology & Life Sciences
Ostatnio aktualizowano29 bal. 2024 @ 09:10

0.00% $ 0.0520

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:10):
Profile picture for Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...

Stats
Dzisiejszy wolumen 762 848
Średni wolumen 1.17M
Kapitalizacja rynkowa 41.88M
EPS $0 ( 2024-02-21 )
Last Dividend $7.15 ( 1993-10-21 )
Next Dividend $0 ( N/A )
P/E -5.20
ATR14 $0.00100 (1.89%)

Prescient Therapeutics Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prescient Therapeutics Finanse

Annual 2023
Przychody: $2.43M
Zysk brutto: $2.43M (99.91 %)
EPS: $-0.00960
FY 2023
Przychody: $2.43M
Zysk brutto: $2.43M (99.91 %)
EPS: $-0.00960
FY 2022
Przychody: $1.89M
Zysk brutto: $1.89M (99.93 %)
EPS: $-0.00790
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $5.72 1990-10-25
Last Dividend $7.15 1993-10-21
Next Dividend $0 N/A
Payout Date 1993-12-31
Next Payout Date N/A
# dividends 2 --
Total Paid Out $12.87 --
Avg. Dividend % Per Year 0.00% --
Score 0.22 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2026-10-05)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.22
Pay Frequency
Sporadic
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OMH.AX Ex Dividend Junior 2023-05-04 Sporadic 0 0.00%
AFG.AX Ex Dividend Junior 2023-09-04 Semi-Annually 0 0.00%
GDG.AX Ex Dividend Junior 2023-09-08 Semi-Annually 0 0.00%
QBE.AX Ex Dividend Knight 2023-08-17 Annually 0 0.00%
BBN.AX Ex Dividend Knight 2023-08-24 Semi-Annually 0 0.00%
JBH.AX Ex Dividend Knight 2023-08-24 Semi-Annually 0 0.00%
SIG.AX Ex Dividend Knight 2023-09-25 Annually 0 0.00%
CIA.AX Ex Dividend Knight 2023-06-13 Semi-Annually 0 0.00%
MMS.AX Ex Dividend Junior 2023-09-07 Annually 0 0.00%
URF.AX No Dividend Player 2023-06-29 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-2.491.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3131.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.3181.500-4.65-6.97[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM10.260.80010.008.00[1 - 3]
quickRatioTTM9.960.80010.008.00[0.8 - 2.5]
cashRatioTTM3.081.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
freeCashFlowPerShareTTM-0.009522.00-0.00476-0.00952[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM1.0001.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-3.711.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.1260.800-2.50-1.996[0.5 - 2]
Total Score-0.920

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-5.511.000-0.6580[1 - 100]
returnOnEquityTTM-0.3182.50-2.99-6.97[0.1 - 1.5]
freeCashFlowPerShareTTM-0.009522.00-0.00317-0.00952[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.9111.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM-2.461.000-10.000[0.1 - 0.5]
Total Score-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej